The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.25
Bid: 10.50
Ask: 12.00
Change: 2.40 (26.67%)
Spread: 1.50 (14.286%)
Open: 9.00
High: 11.40
Low: 9.00
Prev. Close: 9.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

2 Mar 2020 11:45

RNS Number : 6762E
Cantor Fitzgerald Europe
02 March 2020
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cantor Fitzgerald Europe

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Redx Pharma plc

(d) Date dealing undertaken:

28th February 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

REDX ORD 1P

Purchases

50,000

7.5 GBX

7.5 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Nil

Nil

Nil

Nil

Nil

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Nil

Nil

Nil

Nil

Nil

Nil

Nil

Nil

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Nil

Nil

Nil

Nil

Nil

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Nil

Nil

Nil

Nil

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

02nd March 2020

Contact name:

Andy Voong

Telephone number:

0207 894 7798

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFZGGFGZKGGZM
Date   Source Headline
15th Mar 20232:05 pmRNSSecond Price Monitoring Extn
15th Mar 20232:00 pmRNSPrice Monitoring Extension
15th Mar 202310:50 amRNSStatement re: Jounce Therapeutics Press Release
14th Mar 202311:45 amRNSResult of Annual General Meeting
10th Mar 20237:00 amRNSForm 8.3 - Redx Pharma Plc
9th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20232:00 pmBUSForm 8.3 - REDX PHARMA PLC
9th Mar 202311:22 amRNSForm 8 (OPD) - Jounce Therapeutics, Inc
9th Mar 202311:15 amRNSForm 8 (OPD) - Redx Pharma Plc
9th Mar 20238:34 amRNSForm 8.5 (EPT/RI)
9th Mar 20237:00 amRNSForm 8.3 - Redx Pharma plc
8th Mar 20239:05 amRNSSecond Price Monitoring Extn
8th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20238:38 amRNSForm 8.5 (EPT/RI)
8th Mar 20238:16 amRNSForm 8 (OPD) Jounce Therapeutics, Inc.
8th Mar 20237:00 amRNSRXC004 Topline Data From a Phase 2 Module
7th Mar 20238:30 amRNSForm 8.5 (EPT/RI)
3rd Mar 20233:08 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
2nd Mar 20238:09 amRNSForm 8.5 (EPT/RI)
1st Mar 20238:48 amRNSForm 8.5 (EPT/RI)
1st Mar 20237:00 amRNSRedx to Present at Cowen Health Care Conference
28th Feb 20236:03 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20234:58 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20234:47 pmRNSForm 8.3 - Redx Pharma plc
27th Feb 20234:36 pmRNSForm 8.3 - Jounce Therapeutics, Inc
27th Feb 20232:40 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
27th Feb 20238:48 amRNSForm 8.5 (EPT/RI)
24th Feb 20235:18 pmRNSForm 8.3 - REDX Pharma PLC
24th Feb 20233:13 pmRNSReplacement Form 8.3 - Jounce Therapeutics, Inc.
24th Feb 20232:02 pmRNSForm 8.3 - Jounce Therapeutics, Inc.
24th Feb 202310:18 amRNSForm 8.5 (EPT/RI)
24th Feb 20237:00 amRNSForm 8.3 - Redx Pharma plc
23rd Feb 20237:15 amRNSRecommended Business Combination
23rd Feb 20237:01 amRNSRecommended Business Combination
15th Feb 20234:38 pmRNSNotice of AGM
9th Feb 20237:00 amRNSProgress Update on RXC007 Clinical Programme
23rd Jan 20237:00 amRNSRedx to Present at Wnt & ß-Catenin Pathway Summit
21st Dec 20227:00 amRNSNew Grant of Options
20th Dec 20227:00 amRNSFinal Results for the Year Ended 30 September 2022
16th Dec 20227:00 amRNSClinical Trial Agreement with MSD
13th Dec 20227:00 amRNSNotice of Preliminary Results
17th Nov 20227:00 amRNSRedx to Present Poster at IBD Nordic Conference
10th Nov 20222:00 pmRNSRXC004 Phase 2 Combination Arms to Open Enrolment
10th Nov 20227:00 amRNSRedx to Present at Jefferies London
7th Nov 20227:00 amRNSRedx Presenting at AFDD meeting
3rd Nov 20227:00 amRNSRedx to Present RXC004 Phase 1 Combination Data
27th Oct 20227:00 amRNSRedx to Present Poster at ASN Kidney Week
11th Oct 20227:00 amRNSFirst Patient Dosed in Phase 2a Trial for RXC007
3rd Oct 20227:00 amRNSRedx Presents RXC007 Preclinical and Phase 1 Data
29th Sep 20227:41 amRNSRedx to Present Poster on RXC007 at ICLAF

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.